Match!
Mehdi Najafzadeh
Brigham and Women's Hospital
72Publications
16H-index
1,587Citations
Publications 76
Newest
Source
Source
Source
Source
#1Ajinkya Pawar (Brigham and Women's Hospital)H-Index: 4
#2Elisabetta Patorno (Brigham and Women's Hospital)H-Index: 18
Last.Mehdi Najafzadeh (Brigham and Women's Hospital)H-Index: 16
view all 9 authors...
Source
#1Ameet Sarpatwari (Brigham and Women's Hospital)H-Index: 12
#2Jonathan DiBello (Brigham and Women's Hospital)
Last.Aaron S. Kesselheim (Brigham and Women's Hospital)H-Index: 42
view all 5 authors...
Background Some experts have proposed combating rising drug prices by promoting brand–brand competition, a situation that is supposed to arise when multiple US Food and Drug Administration (FDA)-approved brand-name products in the same class are indicated for the same condition. However, numerous reports exist of price increases following the introduction of brand-name competition, suggesting that it may not be effective. We performed a systematic literature review of the peer-reviewed health po...
Source
#1David G. Li (Tufts University)H-Index: 4
#2Mehdi Najafzadeh (Brigham and Women's Hospital)H-Index: 16
Last.Arash Mostaghimi (Brigham and Women's Hospital)H-Index: 11
view all 4 authors...
Abstract Objectives To characterize the trends, drivers, and potential modifiers of increased spending by US Medicare beneficiaries on medicines deemed essential by the World Health Organization. Design Retrospective cost analysis of Medicare Part D Prescriber Public Use File, detailing annual generic and brand name drug prescribing and spending from 2011 through 2015 by Medicare Part D participants who filled prescriptions for WHO essential medicines. Setting US Medicare System. Main outcome me...
Source
#1Elisabetta PatornoH-Index: 18
#2Ajinkya PawarH-Index: 4
Last.Seabastian SchneeweissH-Index: 83
view all 11 authors...
Background: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose cotransporter-2 inhibitor,...
3 Citations
#1Elisabetta Patorno (Brigham and Women's Hospital)H-Index: 18
#2Ajinkya Pawar (Brigham and Women's Hospital)H-Index: 4
Last.Seabastian Schneeweiss (Brigham and Women's Hospital)H-Index: 83
view all 11 authors...
9 CitationsSource
#1Ajinkya PawarH-Index: 4
#2Elisabetta PatornoH-Index: 18
Last.Mehdi NajafzadehH-Index: 16
view all 9 authors...
EMPRISE studies the comparative effectiveness, safety and health care resource utilization of empagliflozin (EMPA) in Medicare and 2 U.S. commercial claims datasets (2014-2019). In this first analysis, we evaluated healthcare costs and medications burden associated with EMPA vs. dipeptidyl peptidase 4 inhibitors (DPP-4i) use in routine care patients with type 2 diabetes (T2D). We identified a 1:1 propensity-score-matched cohort of T2D patients ≥18 years initiating either EMPA or DPP-4i between 0...
Source
12345678